Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07112287) titled 'Germline Testing for Predisposition to Myeloid Malignancies' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Screening. Masking: None (Open Label).
Primary Sponsor: Christopher Reilly
Condition:
Myeloid Malignancy
Genetic Predisposition to Disease
Myeloid Hematological Malignancies
Intervention:
Device: MyeloGen Gene Panel
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: February 2026
Target Sample Size: 200
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2...